T1	Participants 1317 1477	A significant reduction in the incidence of chemotherapy-related oral mucositis occurred across multiple cycles of treatment in patients treated with filgrastim
T2	Participants 0 92	Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
T3	Participants 225 392	We were interested in the potential role of filgrastim (recombinant methionyl human granulocyte colony-stimulating factor, r-metHuG-CSF) in the reduction of mucositis.
T4	Participants 94 223	Mucositis, the inflammation and necrosis of mucosal membranes, is a serious and debilitating consequence of many cancer therapies
